S&P 500   3,776.79 (-0.49%)
DOW   30,895.59 (-0.31%)
QQQ   312.40 (-0.62%)
AAPL   127.90 (-0.78%)
MSFT   213.76 (+0.35%)
FB   251.52 (+2.39%)
GOOGL   1,740.72 (+0.57%)
AMZN   3,104.26 (-0.74%)
TSLA   825.69 (-2.29%)
NVDA   517.82 (-1.93%)
BABA   242.72 (-0.11%)
CGC   33.37 (-3.61%)
GE   11.40 (-2.23%)
MU   81.26 (-0.05%)
AMD   89.18 (-1.77%)
T   29.22 (-0.24%)
NIO   56.14 (-7.77%)
F   9.93 (-2.36%)
ACB   11.93 (-0.25%)
BA   205.18 (-2.25%)
DIS   171.44 (-1.15%)
NFLX   499.87 (-0.20%)
GILD   63.35 (+1.52%)
S&P 500   3,776.79 (-0.49%)
DOW   30,895.59 (-0.31%)
QQQ   312.40 (-0.62%)
AAPL   127.90 (-0.78%)
MSFT   213.76 (+0.35%)
FB   251.52 (+2.39%)
GOOGL   1,740.72 (+0.57%)
AMZN   3,104.26 (-0.74%)
TSLA   825.69 (-2.29%)
NVDA   517.82 (-1.93%)
BABA   242.72 (-0.11%)
CGC   33.37 (-3.61%)
GE   11.40 (-2.23%)
MU   81.26 (-0.05%)
AMD   89.18 (-1.77%)
T   29.22 (-0.24%)
NIO   56.14 (-7.77%)
F   9.93 (-2.36%)
ACB   11.93 (-0.25%)
BA   205.18 (-2.25%)
DIS   171.44 (-1.15%)
NFLX   499.87 (-0.20%)
GILD   63.35 (+1.52%)
S&P 500   3,776.79 (-0.49%)
DOW   30,895.59 (-0.31%)
QQQ   312.40 (-0.62%)
AAPL   127.90 (-0.78%)
MSFT   213.76 (+0.35%)
FB   251.52 (+2.39%)
GOOGL   1,740.72 (+0.57%)
AMZN   3,104.26 (-0.74%)
TSLA   825.69 (-2.29%)
NVDA   517.82 (-1.93%)
BABA   242.72 (-0.11%)
CGC   33.37 (-3.61%)
GE   11.40 (-2.23%)
MU   81.26 (-0.05%)
AMD   89.18 (-1.77%)
T   29.22 (-0.24%)
NIO   56.14 (-7.77%)
F   9.93 (-2.36%)
ACB   11.93 (-0.25%)
BA   205.18 (-2.25%)
DIS   171.44 (-1.15%)
NFLX   499.87 (-0.20%)
GILD   63.35 (+1.52%)
S&P 500   3,776.79 (-0.49%)
DOW   30,895.59 (-0.31%)
QQQ   312.40 (-0.62%)
AAPL   127.90 (-0.78%)
MSFT   213.76 (+0.35%)
FB   251.52 (+2.39%)
GOOGL   1,740.72 (+0.57%)
AMZN   3,104.26 (-0.74%)
TSLA   825.69 (-2.29%)
NVDA   517.82 (-1.93%)
BABA   242.72 (-0.11%)
CGC   33.37 (-3.61%)
GE   11.40 (-2.23%)
MU   81.26 (-0.05%)
AMD   89.18 (-1.77%)
T   29.22 (-0.24%)
NIO   56.14 (-7.77%)
F   9.93 (-2.36%)
ACB   11.93 (-0.25%)
BA   205.18 (-2.25%)
DIS   171.44 (-1.15%)
NFLX   499.87 (-0.20%)
GILD   63.35 (+1.52%)
Log in
OTCMKTS:PKTX

ProtoKinetix Stock Forecast, Price & News

$0.10
0.00 (0.00 %)
(As of 01/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.09
Now: $0.10
$0.10
50-Day Range
$0.09
MA: $0.10
$0.11
52-Week Range
$0.05
Now: $0.10
$0.22
Volume19,232 shs
Average Volume74,526 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in food and crop preservation at freezing temperatures. Its AAGPs have commercial applications in the harvesting, storage, and transplantation of cells, tissues, and organs; and treatments for conditions and diseases caused by stress factors, including UV radiation, oxidation, and inflammation. The company has collaboration agreement with the University of British Columbia to test neuronal retinal cells in living tissue for the treatment of macular degeneration; and research agreement with the University of Dalhousie to examine the effects of AAGP in transplant medicine. It develops AAGP to treat Dry Eye Disease therapy. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was founded in 1999 and is based in Marietta, Ohio.

MarketRank

Overall MarketRank

0.54 out of 5 stars

Medical Sector

1188th out of 1,480 stocks

Biotechnology Industry

26th out of 67 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PKTX
Previous SymbolNASDAQ:PKTX
CUSIPN/A
Phone+1-304-2995070
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$0.10
0.00 (0.00 %)
(As of 01/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PKTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ProtoKinetix (OTCMKTS:PKTX) Frequently Asked Questions

How has ProtoKinetix's stock been impacted by Coronavirus (COVID-19)?

ProtoKinetix's stock was trading at $0.2123 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PKTX shares have decreased by 52.9% and is now trading at $0.10.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than ProtoKinetix?

Wall Street analysts have given ProtoKinetix a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ProtoKinetix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ProtoKinetix?

ProtoKinetix saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 3,000 shares, an increase of 2,900.0% from the December 15th total of 100 shares. Based on an average trading volume of 58,400 shares, the short-interest ratio is presently 0.1 days.
View ProtoKinetix's Short Interest
.

Who are some of ProtoKinetix's key competitors?

What other stocks do shareholders of ProtoKinetix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProtoKinetix investors own include Fulcrum Therapeutics (FULC), Rockwell Medical (RMTI), Provention Bio (PRVB), VIVUS (VVUS), Actinium Pharmaceuticals (ATNM), Chimerix (CMRX), (PCSA), Rexahn Pharmaceuticals (REXN), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Who are ProtoKinetix's key executives?

ProtoKinetix's management team includes the following people:
  • Mr. Clarence Edward Smith, Chairman, CEO & Pres (Age 57)
  • Mr. Michael Richard Guzzetta CPA, Chief Financial Officer (Age 63, Pay $60k)
  • Dr. Jean-Charles Quirion Ph.D., Head of Researchers for Rouen

What is ProtoKinetix's stock symbol?

ProtoKinetix trades on the OTCMKTS under the ticker symbol "PKTX."

How do I buy shares of ProtoKinetix?

Shares of PKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ProtoKinetix's stock price today?

One share of PKTX stock can currently be purchased for approximately $0.10.

What is ProtoKinetix's official website?

The official website for ProtoKinetix is www.protokinetix.com.

How can I contact ProtoKinetix?

ProtoKinetix's mailing address is 412 Mulberry St, MARIETTA, OH 45750-2016, United States. The company can be reached via phone at +1-304-2995070.

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.